Concord Biotech Ltd.

₹1,230.6

-37.9 (-3%)

CONCORDBIO Share Price

Pharmaceuticals & Biotechnology

As on October 29, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 12,866.7 Cr

P/E Ratio49.34

Dividend Yield0.61 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,282.98	Bearish
10-DMA	1,293.37	Bearish
20-DMA	1,328.21	Bearish
50-DMA	1,426.5	Bearish
100-DMA	1,380.65	Bearish
200-DMA	1,268.39	Bearish

Historical Performance

1 Year

-15.3%

3 Years

2.1%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	10,549	12,001	10,169	8,532	7,129
Total Expenditure	6,870	6,932	5,848	5,046	4,390
Other Income	524	444	338	353	234
Operating Profit	4,203	5,513	4,660	3,839	2,973
Interest	8	10	32	98	61
Depreciation	745	544	536	540	500
Profit Before Tax	3,446	4,946	4,126	3,220	2,375
Consolidated Net Profit	2,609	3,716	3,081	2,401	1,749
Adjusted EPS	25	36	29	23	17

Compounded Sales Growth

10 Years:15.5

5 Years:11.3

3 Years:4.3

TTM:-2.5

Compounded Profit Growth

10 Years:9.1

5 Years:2.1

3 Years:1.7

TTM:-6.8

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:1.5

TTM:-15.4

Return on Equity

10 Years:N/A

5 Years:16.7

3 Years:29.5

last year:24.9

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	105	105	105	105	95
Total Reserves	20,066	18,023	15,162	12,795	10,937
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	476	375	319	321	544
Other Current Liabilities	559	550	383	616	660
Short Term Borrowings	---	4	---	---	43
Total Liabilities	22,318	20,343	17,007	15,140	15,019
Capital Work in Progress	782	501	2,115	1,727	742
Long Term Loans & Advances	179	120	128	116	2,210
Currents Investments	4,021	3,165	2,437	1,369	735
Short Term Loans and Advances	302	274	211	157	104
Total Current Assets	12,501	11,352	8,962	7,277	6,327
Total Assets	22,318	20,343	17,007	15,140	15,019
Adjusted Book Value	193	173	146	123	105

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 49.34, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of 1.5%, indicating poor shareholder returns.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹4203 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹10549 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 846413.1

No. of Shares: 688 (Approx)

Performance:-15.4%

-153586.9

NIFTY Performance: -11.4%

1 day Top Gainers